Dangerous Drug Lawsuits - Feeney Law Firm

AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs

Brett Katsma — Fri, 02 Aug 2019 19:26:27 +0000

As pressure continues to mount on Gilead Sciences Inc., one of the largest manufacturers of HIV/AIDS drugs, from withholding improved HIV drugs from the public to increase profits, another foundation is taking the podium. AIDS Healthcare Foundation (AHF) is calling on Gilead to set up a $10 billion compensation fund for victims that took their TDF-based drugs as part of their HIV/AIDS treatment or preventative treatment (PrEP) programs.

The post AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs appeared first on Feeney Law Firm.

Gilead tries—and fails—to dodge lawsuit claiming it delayed safer HIV meds

Brett Katsma — Mon, 24 Jun 2019 21:10:42 +0000

After years of allegations directed towards Gilead Sciences regarding their decision to hold back the release of improved next-gen HIV drugs in order to maximize profits from their older generation drugs, a federal judge has finally allowed a key lawsuit to proceed. 140 patients in 31 states have claimed in the lawsuit that Gilead shelved their newly developed tenofovir alafenamide fumarate (TAF) drugs in 2004 to protect the profits from their existing and older franchise drugs tenofovir disoproxil fumarate (TDF). All the while knowing the TAF-based drugs were safer and better for patients.

The post Gilead tries—and fails—to dodge lawsuit claiming it delayed safer HIV meds appeared first on Feeney Law Firm.

Jury awards $70 million to woman who blamed J&J powder for cancer

Brett Katsma — Mon, 07 Nov 2016 19:48:23 +0000

After only 3 hours of deliberations, a St. Louis jury awarded $70 million in compensation and punitive damages to a California woman who blamed her ovarian cancer on Johnson & Johnson’s talcum powder. This is the third straight trial Johnson & Johnson has lost over claims that its talcum powder can cause ovarian cancer. Earlier this year, juries awarded verdicts of $72 million and $55 million against the company in the first two talcum powder claims to go to trial. All three cases contended that J&J knew there was a risk of ovarian cancer linked to its Baby Powder and Shower to Shower products yet failed to warn customers of that risk. While the company plans to appeal the recent verdict, plaintiffs’ lawyers are hoping these two outcomes will motivate the company to try and settle the nearly 1,700 outstanding talc cases filed against J&J. The company denied any wrongdoing and stated that it takes questions about the safety of its products very seriously.

The post Jury awards $70 million to woman who blamed J&J powder for cancer appeared first on Feeney Law Firm.

J&J’s Janssen Pharmaceuticals Under Fire Again in Risperdal Trial

Brett Katsma — Wed, 20 Jul 2016 20:50:25 +0000

Johnson & Johnson’s Janssen Pharmaceuticals came under fire again when a Philadelphia jury awarded $70 million to the family of a boy who developed breasts while taking the company’s antipsychotic drug Risperdal. Apparently the jury found that Janssen intentionally falsified, destroyed or concealed evidence in the case in reaching its decision. These allegations come after J&J and Janssen already paid over $2.2 billion back in 2013 to resolve civil and criminal investigations by the U.S. Department of Justice into its marketing of Risperdal and several other drugs. The $70 million verdict here dwarfs the next largest jury award in a Risperdal case which was $2.5 million. Perhaps this could be a sign that people are tired of J&J and Janssen putting its revenues ahead of the health and well-being of its consumers. This trend in jury awards could be particularly troubling for the company as J&J is still facing over 12,000 claims regarding Risperdal.

The post J&J’s Janssen Pharmaceuticals Under Fire Again in Risperdal Trial appeared first on Feeney Law Firm.

Jury Awards $70 Million in Risperdal Trial

Brett Katsma — Wed, 20 Jul 2016 20:41:41 +0000

In early July, a jury in a Philadelphia courtroom awarded $70 million to the family of a boy who developed breasts after taking the antipsychotic drug Risperdal. The jury found that the maker of Risperdal, Janssen Pharmaceuticals, failed to warn the boy’s healthcare providers that there was a risk of gynecomastia (breast growth in men) with use of the drug. The boy’s lawyers say he developed gynecomastia at the age of five as a result of taking Risperdal. A Janssen spokeswoman said the $70 million award was “clearly excessive” and said the company plans on asking the court to review it.

The post Jury Awards $70 Million in Risperdal Trial appeared first on Feeney Law Firm.

Jury awards $55 million to woman who blamed talc for cancer

Brett Katsma — Wed, 04 May 2016 17:06:07 +0000

A St. Louis jury awarded a South Dakota woman who blamed her ovarian cancer on Johnson & Johnson’s talcum powder $55 million in compensation and punitive damages. A little less than two months earlier in the same courthouse, the company lost a $72 million verdict to the family of a woman who died of ovarian cancer. Both cases contended that J&J knew the risk of ovarian cancer was linked to its Baby Powder and Shower to Shower products yet failed to warn customers of that risk. While the company plans to appeal the recent verdict, plaintiffs’ lawyers are hoping these two outcomes will motivate the company to try and settle the nearly 1,000 outstanding talc cases filed against J&J. The company denied any wrongdoing and stated that it takes questions about the safety og its products very seriously.

The post Jury awards $55 million to woman who blamed talc for cancer appeared first on Feeney Law Firm.

J&J’s Baby Powder Problem

Brett Katsma — Thu, 07 Apr 2016 19:50:19 +0000

Bloomberg released an investigatory report regarding the potential link between long term use of talcum powder in the genital area and ovarian cancer in women. J&J has been selling its Baby Powder for over 100 years, yet there had never been a discussion concerning ovarian cancer until a British study done in 1971 found talc particles “deeply embedded” in 10 of 13 ovarian tumors.

The post J&J’s Baby Powder Problem appeared first on Feeney Law Firm.

Troubling Allegations in Risperdal Trial

Brett Katsma — Mon, 14 Mar 2016 19:58:09 +0000

The most troubling aspect of a recent case decided against Johnson & Johnson (J&J) concerning its antipsychotic drug Risperdal is the allegation that the company deliberately withheld data from the U.S. Food and Drug Administration. An expert witness testified that J&J knew about the risk of gynecomastia associated with Risperdal but failed to show the complete extent to which young people may develop it when using the drug. This is troubling because it appears to be proof that the company is putting its bottom line ahead of the health and wellbeing of our country’s children. Apparently J&J decided its revenues were more important than the psychological trauma suffered by young men who took Risperdal and had their lives turned upside down when they began to develop breasts. These companies should be held liable for their actions and it was good to see a Philadelphia jury decide accordingly.

The post Troubling Allegations in Risperdal Trial appeared first on Feeney Law Firm.

Jury Awards $2.5 Million in Risperdal Trial

Brett Katsma — Mon, 14 Mar 2016 19:53:20 +0000

The Wall Street Journal reported that a Philadelphia jury held Johnson & Johnson (J&J) liable for failing to warn that its antipsychotic drug Risperdal could cause gynecomastia and ordered the company to pay $2.5 million in damages. The family of an autistic boy who took Risperdal between 2002 and 2006 and later developed size 46DD breasts brought the suit, claiming J&J hid the risks of male breast development with the use of Risperdal in young boys and men. While J&J settled a number of these claims over the past few years, this was the first one to go to trial where J&J was accused of hiding data from the U.S. Food and Drug Administration as well as prescribing doctors and parents. One law school professor from the University of Richmond commented that the verdict “doesn’t bode well for the company,” but cautioned that J&J would most likely want to see more jury verdicts before seriously considering settlement negotiations for the 1,200 similar lawsuits filed against the company. For its part, J&J said it would consider its options going forward, including a possible appeal of the verdict.

The post Jury Awards $2.5 Million in Risperdal Trial appeared first on Feeney Law Firm.

FDA Warns of Ketoacidosis with Certain Diabetes Drugs

kevin — Sun, 03 Jan 2016 06:05:22 +0000

An article on the American Academy of Family Physicians’ website discussed the FDA’s recent move to add warnings to the labels of diabetes drugs like Invokana to notify users about the potential risk of ketoacidosis. The article also cautioned physicians whose patients are on these diabetes drugs to watch for signs of ketoacidosis and to make patients aware of the symptoms so they can seek medical attention should symptoms appear. The FDA also noted that while a number of adverse events have been reported with this particular type of diabetes drug, the actual number of adverse events is most likely higher since the reporting is done on a voluntary basis only.

The post FDA Warns of Ketoacidosis with Certain Diabetes Drugs appeared first on Feeney Law Firm.